TX Houston의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 38개가 Houston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
피험자 모집 중3상
- Research Site, Houston
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
피험자 모집 중1상
- Research Site, Houston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중3상
- MD Anderson Cancer Center, Houston
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
피험자 모집 중1/2상
- MD Anderson, Houston
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
피험자 모집 중3상
- Houston Methodist Hospital, Houston
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
피험자 모집 중3상
- The University of Texas MD Anderson Cancer Center, Houston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
피험자 모집 중4상
- MD Anderson Cancer Center, Houston
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
피험자 모집 중1상
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
피험자 모집 중2상
- The University of Texas MD Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
피험자 모집 중3상
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
피험자 모집 중2상
- MD Anderson Cancer Center, Houston
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
피험자 모집 중1/2상
- MD Anderson Cancer Center, Houston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
피험자 모집 중3상
- University of Texas MD Anderson Cancer Center, Houston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중2상
- University of Texas MD Anderson Cancer Center, Houston
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1/2상
- University of Texas MD Anderson Cancer Center, Houston
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중1/2상
- Research Site, Houston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
피험자 모집 중3상
- Houston Methodist Cancer Center Infusion, Houston
- Houston Methodist Hospital - Department of Pharmacy, Houston
- Houston Methodist Hospital Cancer Center, Houston
- 외 3개
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
피험자 모집 중1/2상
- MD Anderson Cancer Center, Houston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
피험자 모집 중1/2상
- Research Site, Houston
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
피험자 모집 중2상건강한 지원자 환영
- MD Anderson Cancer Center, Houston
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
피험자 모집 중3상
- Research Site, Houston
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
피험자 모집 중1상
- Houston Methodist Hospital, Houston
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
피험자 모집 중1/2상
- M D Anderson Cancer Center, Houston
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
피험자 모집 중2상
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
피험자 모집 중1/2상
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1상
- University of Texas MD Anderson Cancer Center, Houston
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중1상
- Oncology Consultants /ID# 268323, Houston
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
피험자 모집 중3상
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- M D Anderson Cancer Center, Houston
- 외 2개
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
피험자 모집 중3상
- Houston Methodist Hospital, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
피험자 모집 중관찰 연구
- M D Anderson Cancer Center, Houston
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
피험자 모집 중1/2상
- The University of Texas MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
피험자 모집 중1상
- MD Anderson Cancer Center, Houston
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
피험자 모집 중2상
- M D Anderson Cancer Center, Houston
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
피험자 모집 중1/2상
- Houston Methodist Neal Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
피험자 모집 중1/2상
- MDACC, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
피험자 모집 중1/2상
- University of Texas MD Anderson Cancer Center, Houston
다른 도시의 다발성 골수종 시험
- New York City, NY연구 60개
- Boston, MA연구 42개
- Atlanta, GA연구 41개
- Durham, NC연구 37개
- Nashville, TN연구 32개
- Denver, CO연구 27개
- Rochester, MN연구 24개
- St. Louis, MO연구 24개
- Columbus, OH연구 24개
- Baldwin Park, CA연구 23개
- Chicago, IL연구 22개
- Seattle, WA연구 22개
Houston의 다른 연구
- 비소세포폐암연구 145개
- 유방암연구 126개
- 암 (전체)연구 121개
- 전이성 암연구 104개
- 대장직장암연구 102개
- 난소암연구 89개
- 급성 골수성 백혈병연구 85개
- 폐암연구 78개
- 전립선암연구 76개
- 자궁내막암연구 68개
- 췌장암연구 61개
- 흑색종연구 59개
ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.